Rydapt is demonstrated to enhance survival in patients with AML connected to an FLT3 mutation. One particular main analyze, involving 717 such individuals, as opposed Rydapt with placebo (a dummy cure) originally as an addition to other cancer medicines, accompanied by remedy with Rydapt or placebo alone in These whose disease responded. About 51%